MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Indications for CABG in the DES Era
There continues to be a significant role for surgery in the current management of coronary artery disease.
By Michael Mack, MD
Multivessel Interventions
By Ted E. Feldman, MD, Chief Medical Editor
Study Presented of Embolic Protection Devices for SAVR
March 19, 2017—The American College of Cardiology (ACC) announced the presentation of a study demonstrating that two cerebral embolic protection devices that have been cleared by the US Food and Drug Administration for use during surgical aortic valve replacement (SAVR) did not significantly reduce overall number of brain infarcts over standard surgical procedure.
NeuroARC Proposes Classification System for Neurologic Outcomes After Cardiac Procedures
February 6, 2017—The Neurologic Academic Research Consortium (NeuroARC) announced the publication of a consensus paper offering a new classification of neurologic outcomes and testing to better ensure the safety of cardiac procedures.
“No Surprises” in 5-Year PARTNER I Data Presented at ACC
March 15, 2015—The American College of Cardiology (ACC) announced that 5-year data from the PARTNER I clinical trial demonstrated that the Sapien transcatheter heart valve (Edwards Lifesciences) is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open heart surgery; however, valve leakage was more common with the first-generation valve evaluated in this study than with surgery. The PARTNER I data was presented at the ACC’s 64th annual scientific session in San Diego, California.
FDA Approves Investigational Device Exemption for STS/ACC Study of Alternative Access for TAVR
February 14, 2013—The Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC) announced that they have received a unique investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to study alternative access approaches for transcatheter aortic valve replacement (TAVR).
FDA Approves Abbott Vascular's MitraClip
October 25, 2013—Abbott Vascular (Santa Clara, CA) announced that its catheter-based MitraClip therapy has received US Food and Drug Administration approval and will launch immediately in the United States.
Point/Counterpoint: Does the United States Have Enough TAVR Centers?
By Paul J. Pearson, MD, PhD, and D. Craig Miller, MD
Survey of Heart Valve Patients Shows Need for Increased Awareness About Clinical Trial Enrollment
November 5, 2020—Most heart valve patients are not very aware of clinical trials, but most patients would consider enrolling in a clinical trial, according to results of a nationwide survey announced by HeartValveSurgery.com, an advocacy group for patients with heart valve disease.
The Transapical Route for TAVR
Recent data regarding transapical access for transcatheter aortic valve replacement, as well as the devices used in this procedure.
By Rafal Dworakowski, MD, PhD, and Olaf Wendler, MD, PhD, FRCS
The FDA Panel Meeting to Discuss Transcatheter Aortic Valve Implantation
A first-hand European perspective.
By Martyn Thomas, MD, FRCP
Study Shows Unprotected TAVR Procedures Produce New Brain Lesions in Nearly All Cases
October 19, 2015—Keystone Heart Ltd. recently announced that findings from the company-sponsored multicenter Neuro-TAVR study were presented at TCT 2015, the 27th annual Transcatheter Cardiovascular Therapeutics scientific symposium, held October 11–15 in San Francisco, California.
BMJ Publication Questions Safety and Cost-Effectiveness of TAVI, Quality of European and US Regulatory Processes
Year 1 of the TVT Registry
What have we learned, and where do we go from here?
By Eric L. Sarin, MD; Michael J. Mack, MD; Hanna A. Jensen, MD, PhD; and Vinod H. Thourani, MD
Lessons From the TVT Registry
An assessment of the TVT registry, which is studying the real-world outcomes of patients undergoing new valvular therapies.
By David R. Holmes, MD, and Michael J. Mack, MD
TAVR Compared to Surgery in Low-Risk Patients at 2 Years in PARTNER 3 Trial
March 29, 2020—Michael J. Mack, MD, presented 2-year clinical and echocardiographic outcomes from the PARTNER 3 study at the virtual conference of the American College of Cardiology’s (ACC) Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). The PARTNER 3 trial focused on a low-risk patient population.
Three-Year COAPT Data Support Abbott's MitraClip TMVR Device
September 28, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the COAPT trial were presented by coprincipal investigator Michael J. Mack, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
STS/ACC TVT Registry Reports on Initial Edwards Sapien TAVR Outcomes in the United States
November 17, 2013—Outcomes from the Society of Thoracic Surgeons/American College of Cardiology's Transcatheter Valve Therapy (STS/ACA TVT) Registry were presented by Michael J. Mack, MD, at the American Heart Association's Scientific Sessions 2013 in Dallas, Texas and were published by Dr. Mack et al in the Journal of the American Medical Association (JAMA; 2013;310:2069–2077).
ACC and STS Issue Expert Consensus Document on Transcatheter Valve Therapy
June 27, 2011—The American College of Cardiology (ACC) and the Society of Thoracic Surgeons (STS) have published an expert consensus document on transcatheter valve therapy.
PARTNER 3 Compares TAVR and Surgery in Low-Risk Patients With Severe Symptomatic Aortic Stenosis
March 16, 2019—The American College of Cardiology (ACC) announced that the 1-year findings from the PARTNER 3 trial will be presented on March 17 by Martin B. Leon, MD, at the ACC's 68th Annual Scientific Session, being held March 16–18 in New Orleans, Louisiana. The findings have been published online ahead of print by Michael J. Mack, MD, et al in The New England Journal of Medicine.
